NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Clinical trials for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) explained in plain language.
Never miss a new study
Get alerted when new NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) trials appear
Sign up with your email to follow new studies for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough lung cancers: targeted pill challenges chemo
Disease control Recruiting nowThis study is testing whether a new oral drug called daraxonrasib works better than standard chemotherapy (docetaxel) for people with advanced non-small cell lung cancer that has a specific genetic change (RAS mutation) and has stopped responding to initial treatments. About 420 …
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New hope for lung cancer patients when first immunotherapy fails
Disease control Recruiting nowThis study is testing whether adding a new two-in-one immunotherapy drug (QL1706) to standard chemotherapy works better than chemotherapy alone for people with advanced non-small cell lung cancer. It is for patients whose cancer has started growing again after their first treatme…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Anhui Provincial Cancer Hospital • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
New hope for lung cancer patients: targeted therapy trial challenges standard chemotherapy
Disease control Recruiting nowThis study compares a new targeted drug called firmonertinib against standard chemotherapy for people with advanced non-small cell lung cancer who have specific genetic changes (EGFR PACC or L861Q mutations). About 300 participants will be randomly assigned to receive either the …
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE3 • Sponsor: Allist Pharmaceuticals, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Off-the-Shelf cancer treatment trial seeks to tame tough tumors
Disease control Recruiting nowThis early-stage study is testing a new type of cancer treatment called universal CAR-T cells (REVO-UWD-03) for people with advanced liver or lung cancer. The goal is to see if this 'off-the-shelf' therapy, made from healthy donor cells, is safe and can help control these cancers…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: EARLY_PHASE1 • Sponsor: Wondercel Biotech (ShenZhen) • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
First patients to receive new 'Smart Bomb' cancer drug in groundbreaking trial
Disease control Recruiting nowThis is the first study in people to test a new experimental cancer drug called ALX2004. It aims to find a safe dose and see if the drug can help control advanced cancers that have spread and stopped responding to other treatments. The trial will enroll about 170 adults with spec…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE1 • Sponsor: ALX Oncology Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Looking back to see how a lung cancer treatment holds up over time
Disease control Recruiting nowThis study looks back at long-term survival data from a previous trial to see how well a specific immunotherapy drug works over time for patients with advanced squamous non-small cell lung cancer. It involves 109 patients who received the drug combined with chemotherapy as their …
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New hope pill tested for Tough-to-Treat lung cancer
Disease control Recruiting nowThis early-stage study is testing a new oral medication called HJ-004-02 for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation) and has stopped responding to standard treatments. The main goals are to find a safe dose, see how the b…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE1 • Sponsor: Tongji University • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New immune therapy trial opens for Tough-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new immune therapy drug called ADU-1805, both alone and combined with an existing cancer drug (pembrolizumab). It aims to find safe doses and see if the treatment helps control advanced solid tumors that haven't responded to standard treatments…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE1 • Sponsor: Sairopa B.V. • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New pill targets Tough-to-Treat lung cancer mutations
Disease control Recruiting nowThis early-stage study is testing a new oral drug called BH-30643 in adults with advanced non-small cell lung cancer (NSCLC) that has specific genetic changes (EGFR or HER2 mutations). The first part aims to find a safe and effective dose. The second part will see how well the dr…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE1, PHASE2 • Sponsor: BlossomHill Therapeutics • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
Four-Drug attack plus precision radiation targets tough lung cancer
Disease control Recruiting nowThis study is testing a new combination treatment for people with advanced lung cancer that has a specific genetic change (EGFR mutation) and has stopped responding to their first treatment. It combines four drugs (an immunotherapy, a blood vessel blocker, and two chemotherapies)…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
New hope for tough cancers: trial tests Triple-Threat drug combo
Disease control Recruiting nowThis study is testing a new drug, TCC1727, combined with other cancer medications for people with advanced solid tumors that have stopped responding to standard treatments. The first part of the study aims to find the safest and most effective dose. The second part will see how w…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE1, PHASE2 • Sponsor: Beijing Tide Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC
-
New immune cell therapy tested for Tough-to-Treat cancers
Disease control Recruiting nowThis early-stage study is testing a new type of personalized immune cell therapy called CAR-T for people with advanced lung or breast cancer that has stopped responding to standard treatments. The therapy involves collecting a patient's own immune cells, modifying them in a lab t…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: PHASE1 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Mar 13, 2026 15:06 UTC
-
AI and new scans could speed up Life-Saving cancer treatment
Disease control Recruiting nowThis study aims to make a personalized form of radiotherapy for advanced lung cancer faster and more comfortable to deliver. It will test whether using artificial intelligence (AI) tools and a different type of scan can speed up the process of adjusting a patient's radiation plan…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Phase: NA • Sponsor: Universitaire Ziekenhuizen KU Leuven • Aim: Disease control
Last updated Mar 03, 2026 14:07 UTC
-
Scientists probe link between lung cancer genes and deadly clots
Knowledge-focused Recruiting nowThis study aims to understand if specific genetic mutations in a patient's lung cancer make them more likely to develop dangerous blood clots, known as venous thromboembolism (VTE). Researchers will follow 500 people with advanced non-small cell lung cancer (NSCLC) for six months…
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Sponsor: University Of Perugia • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:30 UTC
-
Italian researchers map rare lung cancer mutation
Knowledge-focused Recruiting nowThis Italian study aims to understand how common HER2 gene mutations are in people with advanced non-small cell lung cancer (NSCLC) and to see how doctors currently diagnose and treat these cases. It will observe about 50 patients over a year to gather this information. The goal …
Matched conditions: NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)
Sponsor: Gruppo Oncologico Italiano di Ricerca Clinica • Aim: Knowledge-focused
Last updated Mar 16, 2026 15:25 UTC